Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention

Wang, Frances M.; Yebyo, Henock G.; Ballew, Shoshana H.; Cainzos-Achirica, Miguel; Boyd, Cynthia; Puhan, Milo A.; Matsushita, Kunihiro; Blaha, Michael J.; Schoenborn, Nancy L.

doi:http://dx.doi.org/10.1016/j.ajpc.2023.100468

Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention

License

Citation

Wang FM, Yebyo HG, Ballew SH, Cainzos-Achirica M, Boyd C, Puhan MA, et al. Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention. Am J Prev Cardiol. 2023 Jan 30;13:100468. DOI: 10.1016/j.ajpc.2023.100468

Abstract

Objective: Personalizing preventive therapies for atherosclerotic cardiovascular disease (ASCVD) is particularly important for older adults, as they tend to have multiple chronic conditions, increased risk for medication adverse effects, and may have heterogenous preferences when weighing health outcomes. However, little is known about outcome preferences related to ASCVD preventive therapies in older adults. Methods: In May 2021, using an established online panel, KnowledgePanel, we surveyed older US adults aged 65-84 years without history of ASCVD on outcome preferences related to statin therapy (benefit outcomes to be reduced by the therapy: heart attack, stroke; adverse effects: diabetes, abnormal liver test, muscle pain) or aspirin therapy (benefit outcomes: heart attack, stroke; adverse effects: brain bleed, bowel bleed, stomach ulcer). We used standardized best-worst scores (range of -1 for "least worrisome" to +1 for "most worrisome") and conditional logistic regression to examine the relative importance of the outcomes. Results: In this study, 607 ASCVD-free participants (median age 74, 46% male, 81% White) were included; 304 and 303 completed the statin and aspirin versions of the survey, respectively. For statin-related outcomes, stroke and heart attack were most worrisome (score 0.55; 95% CI 0.51, 0.60) and (0.53; 0.48, 0.58), followed by potential harms of diabetes (-0.07; -0.10, -0.03), abnormal liver test (-0.25; -0.29, -0.20), and muscle pain (-0.77; -0.82, -0.73). For aspirin-related outcomes, stroke and heart attack were similarly most worrisome (0.48; 0.43, 0.52) and (0.43; 0.38, 0.48), followed by brain bleed (0.30; 0.25, 0.34), bowel bleed (-0.31; -0.33, -0.28), and stomach ulcer (-0.90; -0.92, -0.87). Conditional logistic regression and subgroup analyses by age, sex, and race yielded similar results. Conclusions: Older adults generally consider outcomes related to benefits of ASCVD primary preventive therapies-stroke and heart attack-more important than their adverse effects. Integrating patient preferences with risk assessment is an important next step for personalizing ASCVD preventive therapies for older adults.